Exome Asset Management »

Vyne Therapeutics shares owned by Exome Asset Management

Quarter-by-quarter ownership of Vyne Therapeutics (VYNE) shares owned by Exome Asset Management from 13F filings

Historical chart of Exome Asset Management investment in Vyne Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Vyne Therapeutics held by Exome Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Vyne Therapeutics by Exome Asset Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $275k 118k 2.33

More positions owned by Exome Asset Management

Dr Reddys Labs Adr (RDY)
Eli Lilly & Co. (LLY)
ImmunoGen
Cigna Corp (CI)
Celldex Therapeutics Com New (CLDX)
Tg Therapeutics (TGTX)
Rhythm Pharmaceuticals (RYTM)
Alpine Immune Sciences (ALPN)
Dex (DXCM)
Madrigal Pharmaceuticals (MDGL)
Cytokinetics Com New (CYTK)
Inhibrx (INBX)
Structure Therapeutics Sponsored Ads (GPCR)
Rocket Pharmaceuticals (RCKT)
Bridgebio Pharma (BBIO)

View all positions for Exome Asset Management

Top funds holding Vyne Therapeutics

Cormorant Asset Management
Eventide Asset Management
Citadel Advisors
Soleus Capital Management
DSC Advisors
Palo Alto Investors
AlphaCentric Advisors
Exome Asset Management
Susquehanna International
Fred Alger Management
Vanguard Group
Millennium Management
Hrt Financial
Us Bancorp
Bank of America Corporation

View all funds holding Vyne Therapeutics